Topics

Articles

Willis Chandler, AmerisourceBergen’s recently named President of Biopharma Services, Strategic Global Sourcing and Commercial Solutions, talks about the new investments AB is making to build out its capabilities and its new cell and gene therapy service line.

Aligning AB’s Services and Solutions: Willis Chandler

Private-equity-funded conglomerate will offer life sciences commercialization services



Ashfield and Huntsworth Join Forces to Launch Inizio

Dan Cardinal, Melissa McDevitt, and Dan Wetherill are Partners at 

Configuration-driven SaaS, powered by modern data management technology, can enable orphan drug manufacturers to form effective commercial strategies

A Game Changer for Commercial Insights?

Maria Whitman, global head of ZS’s pharmaceutical and biotech practice, talks about the upheaval of the pharma business model and what it means for sales reps; the current skills gap in the marketplace; and how mega-mergers could soon be back on the agenda

Selling and Surviving in the New Pharma Landscape

Leveraging the value healthcare professionals place on scientific content

Seeing the Value of Scientific Content

Catherine Humphries is a Senior Consultant at MMIT (Managed Markets Insight & Technology) where she serves as a trusted advisor for clients solving for payer access and managed care challenges. Cathy is a leader in market research with over 20 years of experience in custom and syndicated pharmaceutical market research. For over a decade, Cathy has focused on providing recommendations to oncology manufacturers. Cathy’s experience has spanned across multiple therapeutic areas including auto-immune diseases, transplantation, cardiology, vaccines, and other indications. As a payer expert, Cathy is always eager to learn, discuss and share ideas on managed care.

Catherine Humphries sheds light on three key market access challenges within the ophthalmology biosimilars space.

Unique Challenges to Market Access for Ophthalmology Biosimilars

Anne Marie Robertson is Senior Vice President, Strategy & Marketing, and Ellen Cappellino is Senior Vice President, Market & Patient Access at EVERSANA™.

By 2024 oncology therapeutic sales will hit $250 billion worldwide, and there will be more than 22 million cancer survivors. But commercializing how these critical therapies come to market to help patients hasn’t changed much in the past 20 years. The industry must do more, write Anne Marie Robertson and Ellen Cappellino

A New Approach to the Commercialization Challenges Facing the Oncology Industry

, which delivers real-time customer intelligence to enable relevant engagement with key people.

Leaders from Janssen, Novartis Gene Therapies, Pierre Fabre, and the German cancer app start-up Mika discuss how they are leveraging data in innovative ways to advance their engagement with the scientific community and their overall commercial operations

Your Engagement Strategy is Only as Good as Your Data

Karina Castagna is SVP Specialty Solutions at OptimizeRx.

What does digital innovation actually mean and how is it changing the way that pharma is interacting with HCPs and patients?

Engaging HCPs to Improve Brand Access and Retention with Digital Point of Care and Sales Technology

An interview with Matthew Aubin of Sonexus™ Access & Patient Support.

Commercial Channels